NCT00651599View on ClinicalTrials.gov

Treatment of Vasomotor Symptoms in Korean Post Menopausal Women

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 31, 2004

Study Completion Date

May 31, 2005

Conditions
Vasomotor Symptoms
Interventions
DRUG

Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)

Treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.

DRUG

Placebo

Placebo treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.

Trial Locations (4)

110-744

Seoul

135-710

Seoul

138-736

Seoul

Unknown

Seoul

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00651599 - Treatment of Vasomotor Symptoms in Korean Post Menopausal Women | Biotech Hunter | Biotech Hunter